Phosphodiesterase (PDE)
Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.
Phosphodiesterase (PDE) Isoform Specific Products
-
Phosphodiesterase (PDE)
(553)
View all products
-
PDE1
(60)
View all products
-
PDE2
(51)
View all products
-
PDE3
(93)
View all products
-
PDE4
(198)
View all products
-
PDE5
(97)
View all products
-
PDE6
(22)
View all products
-
PDE7
(28)
View all products
-
PDE9
(19)
View all products
-
PDE10
(53)
View all products
-
PDE11
(13)
View all products
-
PDE12
(2)
View all products
-
PDE8
(11)
View all products
-
Autotaxin
(36)
View all products
All Product Categories
-
Phosphodiesterase (PDE) Inhibitors
(915)
View all products
-
Phosphodiesterase (PDE) Agonists
(3)
View all products
-
Phosphodiesterase (PDE) Antagonists
(3)
View all products
-
Phosphodiesterase (PDE) Activators
(7)
View all products
-
Phosphodiesterase (PDE) Modulators
(8)
View all products
-
Phosphodiesterase (PDE) Degraders
(4)
View all products
-
Phosphodiesterase (PDE) Controls
(8)
View all products
-
Phosphodiesterase (PDE) Substrates
(4)
View all products
-
Phosphodiesterase (PDE) Ligand
(1)
View all products
-
Phosphodiesterase (PDE) Related Products (1009)
Related Products (1009)
-
Antibodies (4)
-
Phosphodiesterase (PDE) Isoform Comparison
-
Vardenafil hydrochloride trihydrate (Standard)
0 ImagesCat. No.: HY-B0442BRCAS No.: 330808-88-3Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes-.
-
Enpp-1-IN-32
0 ImagesCat. No.: HY-184200Enpp-1-IN-32 is an orally active, selective ENPP-1 inhibitor with an IC50 of 9.5 nM. Enpp-1-IN-32 shows selectivity over ENPP2/ENPP3. Enpp-1-IN-32 blocks cGAMP hydrolysis, and activates the STING pathway. Enpp-1-IN-32 exhibits antitumor effects in syngeneic mouse models. Enpp-1-IN-32 can be used for the research of triple-negative breast carcinoma.
-
TDP1-IN-5
0 ImagesCat. No.: HY-183334CAS No.: 3115524-78-9TDP1-IN-5 is a tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 of 2.2 μM. By targeting TDP1 both intracellularly and extracellularly, TDP1-IN-5 inhibits the NHEJ repair pathway, arrests the cell cycle at the G2/M phase, upregulates PIG3 to enhance ROS, and ultimately significantly potentiates ionizing radiation (IR)-induced DNA damage and apoptosis. TDP1-IN-5 can be used in the research of colorectal cancer.
-
PDEδ-IN-1
0 ImagesCat. No.: HY-175689CAS No.: 903157-37-9PDEδ-IN-1 is the ligand of PDEδ. PDEδ-IN-1 can be used to synthesize PDEδ autophagic degrader 1 (HY-157458).
-
Mirodenafil-d7
0 ImagesCat. No.: HY-14930SCAS No.: 1329651-11-7Synonyms: SK3530-d7Mirodenafil-d7 (SK3530-d7) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
-
Parogrelil hydrochloride
0 ImagesCat. No.: HY-111219CAS No.: 139145-84-9Synonyms: NM-702; NT-702Parogrelil (hydrochloride) (NM-702) is a phosphodiesterase inhibitor with activity in inhibiting intermittent claudication. Parogrelil (hydrochloride) selectively inhibits PDE3, inhibits human platelet aggregation in vitro and rat aortic contraction, and improves walking distance and plantar surface temperature in the rat femoral artery ligation model, with better effects than cilostazol.
-
AMG-7980
0 ImagesCat. No.: HY-18037CAS No.: 947192-73-6AMG-7980 exhibits high affinity to phosphodiesterase 10A (PDE10A), with a KD of 0.94 nM. AMG-7980 can be used as a tracer of PDE10A, when labeled with radioactive isotope.
-
Avanafil (Standard)
0 ImagesSynonyms: TA1790 (Standard)Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
-
Deltasonamide 1 TFA
0 ImagesCat. No.: HY-122641DCAS No.: 2235358-73-1Deltasonamide 1 TFA is a PDE6δ-KRas inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a KD of 203 pM. Deltasonamide 1 can be used for the research of tumors.
-
ATX inhibitor 10
0 ImagesCat. No.: HY-143583CAS No.: 2648969-30-4ATX inhibitor 10 is a potent inhibitor of ATX. ATX inhibitor 10 is s nitrogen-containing heterocyclic compound. ATX plays a role in causing pathological conditions including fibrosis, arthritis, neurodegeneration, neuropathic pain, and cancer. ATX inhibitor 10 has the potential for the research of ATX related diseases (extracted from patent WO2021115375A1, compound 35).
-
PF-03049423 free base
0 ImagesPF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke.
-
ATX inhibitor 18
0 ImagesCat. No.: HY-146205CAS No.: 2402772-30-7ATX inhibitor 18 is a potent ATX inhibitor with an IC50 value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis.
-
Enpp-1-IN-7
0 ImagesCat. No.: HY-145065Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51).
-
PDE4B-IN-6
0 ImagesCat. No.: HY-179504PDE4B-IN-6 (compound 4i) is a potent and selective PDE4B inhibitor with an IC50 of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over PDE4A (IC50 = 1540 nM) and PDE4C (IC50 = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research.
-
PDE4-IN-36
0 ImagesCat. No.: HY-186214CAS No.: 3034837-81-2PDE4-IN-36 is a phosphodiesterase 4 (PDE4) inhibitor with significant inhibitory activity at 10 μM. PDE4-IN-36 can be used in the research of psoriasis and atopic dermatitis.
-
PDE4-IN-12
0 ImagesCat. No.: HY-151174CAS No.: 2901084-32-8
-
Xanthoanthrafil-d3
0 ImagesCat. No.: HY-136520SCAS No.: 1216710-83-6Xanthoanthrafil-d3 is the deuterium labeled Xanthoanthrafil (HY-136520B). Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC50 of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction.
-
MDL 19205
0 ImagesCat. No.: HY-105057CAS No.: 84490-12-0MDL 19205 is a cardiotonic agent with inotropic effect. MDL 19205 can be used for the research of cardiovascular disease, such as heart failure.
